ES2119094T3 - Inhibicion de la hemorragia uterina disfuncional. - Google Patents

Inhibicion de la hemorragia uterina disfuncional.

Info

Publication number
ES2119094T3
ES2119094T3 ES94309475T ES94309475T ES2119094T3 ES 2119094 T3 ES2119094 T3 ES 2119094T3 ES 94309475 T ES94309475 T ES 94309475T ES 94309475 T ES94309475 T ES 94309475T ES 2119094 T3 ES2119094 T3 ES 2119094T3
Authority
ES
Spain
Prior art keywords
dysfunctional uterine
inhibition
uterine hemorrhage
pirrolidine
hexamethyleneimine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94309475T
Other languages
English (en)
Inventor
Patrick Peter Keohane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2119094T3 publication Critical patent/ES2119094T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

UN METODO PARA INHIBIR LA FUGA UTERINA DISFUNCIONAL COMPRENDIENDO ADMINISTRAR A UNA MUJER EN LA NECESIDAD DE TRATAMIENTO UNA CANTIDAD EFECTIVA DE UN COMPONENTE QUE TIENE LA FORMULA (I) EN DONDE EN DONDE R1 Y R3 SON INDEPENDIENTEMENTE HIDROGENO, -CH3, (ALQUILO C1-C6)-CO O CO-AR, EN DONDE AR ES FENILO OPCIONALMENTE SUSTITUIDO; R2 ES SELECCIONADO DEL GRUPO QUE CONSTA DE PIRROLIDINA, HEXAMETILENEIMINO, Y PIPERIDINO; O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE SU SOLVENTE.
ES94309475T 1993-12-21 1994-12-19 Inhibicion de la hemorragia uterina disfuncional. Expired - Lifetime ES2119094T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,391 US5446053A (en) 1993-12-21 1993-12-21 Methods of inhibiting dysfunctional uterine bleeding

Publications (1)

Publication Number Publication Date
ES2119094T3 true ES2119094T3 (es) 1998-10-01

Family

ID=22623570

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94309475T Expired - Lifetime ES2119094T3 (es) 1993-12-21 1994-12-19 Inhibicion de la hemorragia uterina disfuncional.

Country Status (20)

Country Link
US (2) US5446053A (es)
EP (1) EP0659417B1 (es)
JP (1) JPH07215858A (es)
KR (1) KR950016726A (es)
CN (1) CN1109752A (es)
AT (1) ATE168887T1 (es)
AU (1) AU692490B2 (es)
CA (1) CA2138510A1 (es)
CZ (1) CZ321094A3 (es)
DE (1) DE69412049T2 (es)
DK (1) DK0659417T3 (es)
ES (1) ES2119094T3 (es)
GR (1) GR3027706T3 (es)
HU (1) HUT71469A (es)
IL (1) IL112037A (es)
NO (1) NO944930L (es)
NZ (1) NZ270167A (es)
PH (1) PH31099A (es)
RU (1) RU94044456A (es)
ZA (1) ZA9410080B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5847007A (en) 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
AU6277396A (en) 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
EP1133996A4 (en) * 1998-11-26 2003-04-02 Teikoku Hormone Mfg Co Ltd DRUG COMPOSITIONS WITH PERIODIC ADMINISTRATION
AU777770C (en) 1999-05-04 2005-11-10 Strakan International Limited Androgen glycosides and androgenic activity thereof
IN191020B (es) 2000-03-28 2003-09-13 Dabur Res Foundation
JP2004531562A (ja) * 2001-05-22 2004-10-14 イーライ・リリー・アンド・カンパニー ２−置換１，２，３，４−テトラヒドロキノリンおよびその誘導体、組成物ならびに方法
PT1401446E (pt) * 2001-05-22 2005-05-31 Lilly Co Eli Derivados de tetrahidroquinolina para a inibicao de doencas associadas com a privacao de estrogenio ou com uma resposta fisiologica aberrante ao estrogenio endogeno
TW200407124A (en) * 2002-06-25 2004-05-16 Wyeth Corp Use of thio-oxindole derivatives in treatment of hormone-related conditions
KR102295878B1 (ko) 2021-06-16 2021-08-31 최경선 셀프용 등 지압기

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4859585A (en) * 1986-04-17 1989-08-22 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
IL112037A0 (en) 1995-03-15
EP0659417A2 (en) 1995-06-28
DE69412049T2 (de) 1999-01-14
HUT71469A (en) 1995-11-28
US5446053A (en) 1995-08-29
ZA9410080B (en) 1996-06-19
IL112037A (en) 1999-03-12
EP0659417A3 (en) 1995-09-06
NO944930D0 (no) 1994-12-19
AU8156194A (en) 1995-06-29
RU94044456A (ru) 1996-10-10
PH31099A (en) 1998-02-05
EP0659417B1 (en) 1998-07-29
KR950016726A (ko) 1995-07-20
CA2138510A1 (en) 1995-06-22
NO944930L (no) 1995-06-22
AU692490B2 (en) 1998-06-11
JPH07215858A (ja) 1995-08-15
US5552416A (en) 1996-09-03
CN1109752A (zh) 1995-10-11
HU9403663D0 (en) 1995-02-28
DK0659417T3 (da) 1998-12-07
NZ270167A (en) 1997-08-22
DE69412049D1 (de) 1998-09-03
CZ321094A3 (en) 1995-08-16
ATE168887T1 (de) 1998-08-15
GR3027706T3 (en) 1998-11-30

Similar Documents

Publication Publication Date Title
ES2119094T3 (es) Inhibicion de la hemorragia uterina disfuncional.
ES2101449T3 (es) Inhibicion de la seborrea y el acne.
ES2102154T3 (es) Inhibicion de trombina.
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
DE69620241D1 (de) Gonadotropin releasing hormon- antagonisten
KR950701317A (ko) 인돌 유도체(Indole Derivative)
BR9811099A (pt) Inibidores de urocinase
CO5050303A1 (es) Composicion farmaceutica para tratar infecciones virales y metodos para su preparacion su aplicacion
GEP20022824B (en) Antipicornaviral Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treatment
KR950010892A (ko) 자궁 섬유증 억제 방법
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
ATE229331T1 (de) Inhibitoren von metazoan-parasit-proteasen
KR950010891A (ko) 내성 종양을 치료하는 방법
KR970705384A (ko) 골 보철 파손의 억제 방법(methods for inhibiting bone prosthesis degeneration)
EA199900374A1 (ru) Ингибитор вторичной катаракты
AR003812A1 (es) Uso de los compuestos de 2-fenil-3-benzoil-benzotiofeno-6-sustituidos y sus sales farmaceuticamente aceptables para inhibir el inhibidor de activacion delplasminogeno 1.
KR950016728A (ko) 여성에서 다모증 및 탈모증을 억제하는 방법
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701333A (es) Metodos para inhibir el daño neuronal.
MX9701327A (es) Metodos para inhibir el cancer endometrial.
DK0771201T3 (da) Anvendelse af 2-phenyl-3-aroylbenzothiophener til fremstilling af et medikament til inhibering af primær endometrisk hyperplasi
UY26735A1 (es) Métodos y composiciones para tratar flavivirus y pestivirus
DK0774969T3 (da) HIV-proteaseinhibitor kombination
ECSP961892A (es) Procedimientos para inhibir el inhibidor del activador del plasminogeno 1
DK0772438T3 (da) Anvendelse af benzothiophener til fremstilling af et medikament til reduktion af ardannelse under sårheling

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 659417

Country of ref document: ES